Compare ArcelorMittal SA (MT) vs TG Therapeutics Inc (TGTX) Price & Performance

ArcelorMittal (MT) trades at $74.25, up 0.47% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings missed estimates, but revenue grew year-over-year, and the company maintains a positive outlook for H2 2026. Valuation ratios like P/S of 0.9 and P/B of 1.01 suggest reasonable pricing relative to sales and book value.

The outlook is cautiously optimistic with analyst consensus leaning Buy (50%) amid expectations of European business improvement and strategic expansions. Key risks include volatile steel demand, high capital expenditures, and macroeconomic pressures. Net cash flow remains negative, though operational cash generation is stable. Investors should weigh growth initiatives against cyclical industry headwinds.

TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.

The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.